ArtNr |
PTM-1014 |
Hersteller |
PTM Biolabs
|
Menge |
100 ul |
Format |
Lyophilized powder |
Applikationen |
WB |
Specific against |
Human (Homo sapiens) |
Host |
Rabbit |
Isotype |
IgG |
Konjugat/Tag |
Unconjugated |
Alias |
H3-3A, H3.3A, H3F3, H3F3A, H3-3B, H3.3B, H3F3B |
Versandbedingung |
Raumtemperatur |
Lieferbar |
|
Manufacturer - Type |
Primary Antibodies |
Manufacturer - Category |
Histone & Histone Modification Antibodies |
Manufacturer - Targets |
Histone H3.3 |
Shipping Temperature |
Ambient temperature |
Storage Conditions |
Store at -20°C. Avoid freeze/thaw cycles. |
Molecular Weight |
15 |
Manufacturer - Research Area |
Epigenetics |
Product description |
K36M mutant of histone H3.3 is an "oncohistone" identified in more than 90% of chondroblastoma, a rare type of benign tumor caused by cartilage-producing cells. The mutant inhibits at least two H3K36 methyltransferases MMSET/WHSC1 and SETD2, triggering a depletion of H3K36 methylation and an increase of H3K27 trimethylation. H3.3K36M mutant proteins further alters expression of various genes including BMP2 that regulate oncogenesis and chondrogenesis. Chondrocytes expressing H3.3K36M exhibit several cancer-associated cellular phenotypes, including increased ability to form colonies, resistance to staurosporine-induced apoptosis, and defects in differentiation. |
Purification Method |
Protein A and immunogen affinity purified |
Manufacturer - Specificity |
Anti-Histone H3.3 (Mutated K36M) Rabbit pAb detects endogenous levels of K36M mutants of histone H3.1, H3.2, and H3.3 proteins. |
Constituents |
PBS, Glycerol, BSA |
PTM |
Unmodified |
Immunogen |
Synthetic peptide corresponding to human histone H3.3 K36M mutant |
Clonality |
Polyclonal |
Stability |
Stable for 12 months from date of receipt/reconstitution. |
Background |
K36M mutant of histone H3.3 is an "oncohistone" identified in more than 90% of chondroblastoma, a rare type of benign tumor caused by cartilage-producing cells. The mutant inhibits at least two H3K36 methyltransferases MMSET/WHSC1 and SETD2, triggering a depletion of H3K36 methylation and an increase of H3K27 trimethylation. H3.3K36M mutant proteins further alters expression of various genes including BMP2 that regulate oncogenesis and chondrogenesis. Chondrocytes expressing H3.3K36M exhibit several cancer-associated cellular phenotypes, including increased ability to form colonies, resistance to staurosporine-induced apoptosis, and defects in differentiation. |
Cellular Localization |
Nucleus |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.